Multinational pharmaceutical companies to prepare for the age of anticancer antibody

Published: 2015-11-19 15:45:23

Updated: 2015-11-19 15:45:23

Multinational pharmaceutical companies, which entered the anticancer field with anticancer immunotherapies, have made severe competition to preoccupy the market.

Recently, MSD Korea acquired approval to conduct clinical trials of ‘Keytruda(pembrolizumab)’ an anti-PD-1 immunotherapy, called ‘KEYNOTE-177,’ from the Ministry of Food and Drug Safety.

According to the MSD, every clinical trial for...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.